Darren Snellgrove

Vice President of Investor Relations, Johnson & Johnson

Search every verified Darren Snellgrove interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Darren Snellgrove, vice president of investor relations for Johnson & Johnson, led the company's second quarter 2025 earnings call on July 21, 2025. He introduced himself as the new leader of the investor relations team and opened the presentation, which covered the company's business results and updated financial outlook. During the call, he noted the company's operational sales growth of 4.6% and highlighted that the innovative medicine segment reported 3.8% operational sales growth, exceeding $15 billion in quarterly sales for the first time. He also stated that Johnson & Johnson increased its reported adjusted earnings per share estimate by 25 cents to $10.85, or 8.7% at the midpoint, citing operational improvement and favorable foreign currency dynamics. Snellgrove also discussed the company's performance relative to the loss of exclusivity for Stelara, describing it as a situation where no other healthcare company has grown through the loss of exclusivity of a multi-billion dollar product in its first year. He referenced ongoing momentum in immunology, including plans for a broad phase three campaign in ulcerative colitis and Crohn's disease based on data from a recent study. Additionally, he mentioned upcoming milestones expected in the second half of the year, including approvals and submissions in areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular treatments.